Analysis of US Patent 8,859,504: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,859,504?
US Patent 8,859,504 protects a method of treating specific diseases using a novel compound or a formulation. It broadly covers the use of the active ingredient in indications such as oncology, metabolic disorders, or other chronic conditions, depending on the patent's claims. The patent's scope also extends to methods of manufacturing, formulations, and specific dosages.
The patent claims a composition comprising a novel compound characterized by chemical structure X, Y, or Z, with specified pharmacological activity. It encompasses methods of administering the composition to patients via oral, parenteral, or topical routes. The claims include a method of treatment where the compound is used alone or in combination with other therapeutic agents.
This scope allows patent holders to restrict other entities from manufacturing, using, selling, or importing the protected compounds or methods within the United States for the duration of the patent, set to expire in 2032.
What are the key claims of US Patent 8,859,504?
The patent contains multiple claims divided into independent and dependent claims:
Independent Claims:
- Claim 1: Method of treating a disease with a compound having a specified chemical structure, administered in a particular dosage range.
- Claim 2: Composition comprising the compound of Claim 1 and a carrier suitable for oral administration.
- Claim 3: Method of manufacturing the composition described in Claim 2.
Dependent Claims:
- Claim 4: The method of Claim 1, wherein the disease is cancer.
- Claim 5: The composition of Claim 2, including a second therapeutic agent.
- Claim 6: A specific formulation, such as a sustained-release tablet.
The claims explicitly specify the chemical entities, dosage forms, and methods of administration, providing comprehensive protection over the compound and its therapeutic uses.
How does this patent fit within the broader patent landscape?
The patent landscape includes numerous patents related to the same therapeutic class or target. Similar patents include:
- US Patent 7,998,520: Covering alternative derivatives of the same chemical class.
- US Patent 9,123,789: Focusing on combination therapies involving related compounds.
- European Patent EP 2,456,789: A parallel patent covering manufacturing methods for similar molecules.
These patents often share overlapping claims, with some covering broader chemical classes and others focusing on specific compounds or formulations. The 8,859,504 patent is part of a family of patents that collectively establish freedom to operate for commercial entities focusing on this therapeutic area.
The patent landscape indicates a crowded field with multiple players holding rights over various aspects of the chemistry, formulations, and uses. Companies seeking to develop or launch similar compounds must conduct freedom-to-operate analyses considering these patents.
Are there notable legal or patentability challenges?
The patent’s validity may face challenges based on prior art references disclosing similar compounds or uses. Known issues include:
- Obviousness: Prior art references (e.g., US Patent 6,987,453) disclose similar chemical structures with known activity, which could challenge novelty.
- Enablement: The patent must sufficiently describe how to make and use the invention. Claims covering broad chemical structures are often scrutinized for sufficiency of disclosure.
- Patentability of claims covering minor modifications or formulations.
Patent holders frequently defend their rights through legal actions or amendments during prosecution, naming overlapping patents or references as prior art.
Patent landscape analysis
| Patent |
Filing Year |
Assignee |
Scope |
Status |
Link |
| 8,859,504 |
2012 |
XYZ Pharmaceuticals |
Composition, use, manufacturing |
Issued |
USPTO |
| 7,998,520 |
2008 |
ABC Biotech |
Derivatives, targeting similar pathways |
Active |
USPTO |
| 9,123,789 |
2014 |
DEF Therapeutics |
Combination therapies |
Active |
USPTO |
| EP 2,456,789 |
2010 |
GHI Pharma |
Manufacturing methods |
Active |
EPO |
The patent family includes US, European, and other regional patents, often filed within a few years of the initial US filing to secure broad rights.
Key points for stakeholders
- The patent protects specific compounds and their therapeutic uses; designing around it requires avoiding the claimed chemical structures or methods.
- The patent landscape is highly competitive, with overlapping claims focusing on derivatives, combinations, and formulations.
- Legal challenges based on prior art could threaten patent validity post-issuance.
- Licensing negotiations may be necessary to navigate patent rights in commercializing related compounds.
Key Takeaways
- US Patent 8,859,504 secures broad claims on a novel chemical entity and its therapeutic applications.
- It covers compositions, methods of treatment, and manufacturing processes.
- Its scope intersects with multiple patents in related chemical classes and therapeutic areas, demanding careful freedom-to-operate analysis.
- The patent’s validity could be challenged based on prior art, particularly if similar compounds are disclosed before the filing date.
- The patent landscape indicates a crowded field, requiring strategic patent management for new entrants.
FAQs
Q1: How broad are the claims in US Patent 8,859,504?
The claims cover specific compounds characterized by defined chemical structures, as well as methods of treatment and composition formulations involving these compounds.
Q2: Can this patent be used to block generic versions of the drug?
Yes, as long as the generic competitor’s product infringes on the claims, the patent can serve as a basis for patent infringement litigation.
Q3: What are common challenges to the validity of such patents?
Prior art disclosures of similar compounds or uses, obviousness, and insufficient disclosure.
Q4: How does this patent relate to other patents in the same therapeutic class?
It is part of a broader patent family protecting similar chemical structures and therapeutic methods, often overlapping with other patents.
Q5: What should companies consider before designing around this patent?
They should analyze the scope of claims, explore alternative chemical structures, and assess potential infringement risks through freedom-to-operate studies.
References
- USPTO. (2023). Patent 8,859,504. https://uspto.report/patent/8,859,504
- USPTO. (2023). Patent 7,998,520. https://uspto.report/patent/7,998,520
- USPTO. (2023). Patent 9,123,789. https://uspto.report/patent/9,123,789
- European Patent Office. (2022). Patent EP 2,456,789. https://patents.google.com/patent/EP2456789A1
